Analysts think CRVO stock price could increase by 520%
Dec 05, 2024, 12:25 PM
-75.88%
What does CRVO do
CervoMed, a Boston-based biotechnology company with 8 employees, focuses on developing neflamapimod for neurodegenerative diseases and is conducting the RewinD-LB Phase 2b trial for dementia with Lewy bodies. The drug aims to modify disease processes and improve synaptic dysfunction.
8 analysts think CRVO stock price will increase by 520.41%. The current median analyst target is $60.18 compared to a current stock price of $9.70. The lowest analysts target is $34.34 and the highest analyst target is $73.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!